Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: To investigate and measure the metabolism of colorectal cancer liver metastases using 18F-fluorodeoxyglucose positron emission tomography (FDG PET), before and during the first month of chemotherapy. The findings were compared with tumor outcome conventionally assessed using changes in tumor size. PATIENTS AND METHODS: Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break. Before and at 1 to 2 and 4 to 5 weeks on treatment, FDG PET scans were performed. Patients fasted, were injected intravenously with FDG (50 to 100 MBq), and scanned using a large-area positron camera; the image data was processed such that regions of interest could be identified. The results were expressed as a ratio of FDG uptake in the tumor and normal liver (T:L) or as a semiquantitative standardized uptake value (SUV). These measures were compared with the tumor dimensions measured on a computed tomographic (CT) scan performed at 12 weeks from commencement of chemotherapy. RESULTS: Twenty patients were studied; however, two did not have assessable liver metastases. Objective partial responses were observed in 11 of 18 patients. A total of 27 metastatic lesions were assessable. Pretreatment T:L ratios and SUVs did not correlate with tumor response, although response was associated with lower 1- to 2-week (1.84 v 2.17; t=2.667; P < .02) and 4- to 5-week (1.36 v 2.28; t=5.02; P < .001) T:L ratios, and 4- to 5-week (3.57 v 4.95; t=2.492; P < .05) SUVs. Expressed as a percent of the baseline values of the T:L ratio, responding lesions had a greater reduction in metabolism (67% v 99%; t=7.53; P < .001). The 4- to 5-week T:L ratio was able to discriminate response from nonresponse both in a lesion-by-lesion and overall patient response assessment (sensitivity 100%; specificity 90% and 75%, respectively). CONCLUSION: Positron emission tomography used to evaluate the uptake of FDG in tumors yields data that correlate with the antitumor effect of chemotherapy in patients with liver metastases from colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamacher, K., Coenen, H. H., & Stöcklin, G. (1986) · PubMed · Cited by 1,351
(1992) · PubMed Central · doi:10.2967/jnumed.120.251744a · Cited by 1,172
The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?
Hamberg, L. M., Hunter, G. J. S., Alpert, N. M., Choi, N. C., Babich, J. W., & Fischman, A. J. (1994) · PubMed · Cited by 395
Robb, R. A., Hanson, D. P., Karwoski, R. A., Larson, A. G., Workman, E. L., & Stacy, M. C. (1989) · Computerized Medical Imaging and Graphics · doi:10.1016/0895-6111(89)90285-1 · Cited by 315
Higashi, K., Clavo, A. C., & Wahl, R. L. (1993) · PubMed · Cited by 310
Recurrence of colorectal tumors: PET evaluation.
Strauss, L. G., Clorius, J. H., Schlag, P., Lehner, B., Kimmig, B., Engenhart, R., Marin-Grez, M., Helus, F., Oberdorfer, F., & Schmidlin, P. (1989) · Radiology · doi:10.1148/radiology.170.2.2783494 · Cited by 268
Okazumi, S., Isono, K., Enomoto, K., Kikuchi, T., Ozaki, M., Yamamoto, H., Hayashi, H., Asano, T., & Ryu, M. (1992) · PubMed · Cited by 257
Haberkorn, U., Strauss, L. G., Dimitrakopoulou, A., Engenhart, R., Oberdorfer, F., Ostertag, H. J., Romahn, J., & KAICK, G. V. (1991) · PubMed · Cited by 241
[18F]Fluorodeoxyglucose Uptake in Tumors
Minn, H. R. I., Leskinen-Kallio, S., Lindholm, P., Bergman, J., Ruotsalainen, U., Teräs, M., & Haaparanta‐Solin, M. (1993) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199301000-00021 · Cited by 72
Cited by
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Self-citationImaging proliferation in vivo with [F-18]FLT and positron emission tomography
Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H.-J., Stayanoff, J. C., Lawhorn-Crews, J. M., Obradovich, J. E., Muzik, O., & Mangner, T. J. (1998) · Nature Medicine · doi:10.1038/3337 · Cited by 1,204
(2001) · PubMed · Cited by 943
Positron-Emission Tomography and Assessment of Cancer Therapy
Juweid, M. E., & Cheson, B. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 750
Weber, W. A., Ott, K., Becker, K., Dittler, H.-J., Helmberger, H., Avril, N. E., Meisetschläger, G., Busch, R., Siewert, J.-R., Schwaiger, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3058 · Cited by 701
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Larson, S. (1999) · Clinical Positron Imaging · doi:10.1016/s1095-0397(99)00016-3 · Cited by 598
Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 518
Smith, I. C., Welch, A. E., Hutcheon, A. W., Miller, I. D., Payne, S., Chilcott, F., Waikar, S., Whitaker, T., Ah-See, A. K., Eremin, O., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1676 · Cited by 406
Clinical Role of FDG PET in Evaluation of Cancer Patients
Kostakoglu, L., Agress, H., & Goldsmith, S. J. (2003) · RadioGraphics · doi:10.1148/rg.232025705 · Cited by 402
Selzner, M., Hany, T. F., Wildbrett, P., McCormack, L., Kadry, Z., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000146145.69835.c5 · Cited by 348
Bar-Shalom, R., Valdivia, A. Y., & Blaufox, M. D. (2000) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2000.7439 · Cited by 340
Downey, R. J., Akhurst, T., Ilson, D., Ginsberg, R., Bains, M. S., Gonen, M., Koong, H., Gollub, M., Minsky, B. D., Zakowski, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.013 · Cited by 320
Ott, K., Fink, U., Becker, K., Stahl, A., Dittler, H.-J., Busch, R., Stein, H., Lordick, F., Link, T., Schwaiger, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.574 · Cited by 318
Positron Emission Tomography As an Imaging Biomarker
Weber, W. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6068 · Cited by 312
Clinical role of positron emission tomography in oncology
Bomanji, J., Costa, D., & Ell, P. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00257-6 · Cited by 281
Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging
Cook, G. J. R., Wegner, E. A., & Fogelman, I. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2003.12.003 · Cited by 258
PET and PET-CT for evaluation of colorectal carcinoma
Delbeke, D., & Martin, W. H. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2004.03.006 · Cited by 110
Metadata
- Authors
- Findlay, M., Young, H., Cunningham, D., Iveson, A., Cronin, B., Hickish, T., Pratt, B., Husband, J., Flower, M., & Ott, R.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-03
- Volume
- 14
- Issue
- 3
- Pages
- 700-708
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1772207639
- Cited by
- 310
- References
- 9
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.